Skip to content
PeptideAgent

Compounding pharmacies in Massachusetts

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

The Massachusetts Board of Registration in Pharmacy (Department of Public Health) regulates compounding pharmacies in Massachusetts. Compounded GLP-1 limited. How to check a pharmacy's license, plus verified listings.

Massachusetts at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async unclear
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Verified compounding pharmacies serving Massachusetts

No verified compounding pharmacies serving Massachusetts are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Who regulates compounding pharmacies in Massachusetts

The Board of Registration in Pharmacy licenses pharmacies under M.G.L. chapter 112, sections 24 through 42D, and Board regulations in 247 CMR, including 247 CMR 6.00 (licensure of pharmacies) and 247 CMR 9.00 (professional practice standards, including non-resident pharmacies). Chapter 159 of the Acts of 2014, An Act relative to pharmacy practice in the Commonwealth, passed after the New England Compounding Center meningitis outbreak, inserted sections 39D through 39J into chapter 112: section 39G created a license for retail sterile compounding pharmacies, section 39H a license for retail complex non-sterile compounding pharmacies, section 39I a license for institutional sterile compounding pharmacies, and section 39J non-resident pharmacy licensure. Under section 39J(d), no pharmacy, pharmacist, or outsourcing facility outside Massachusetts may ship, sell, or dispense sterile or complex non-sterile drug preparations into the state unless they were compounded in a facility holding a Massachusetts nonresident sterile compounding license, nonresident complex non-sterile compounding license, or nonresident outsourcing facility registration. 247 CMR 17.00 (sterile compounding) and 247 CMR 18.00 (non-sterile compounding) are posted on the Board's draft regulations page and are not in the Trial Court Law Libraries compilation of current 247 CMR checked on 2026-09-22, so this record treats them as drafts, not adopted rules. Massachusetts has no state bulks list, so peptide eligibility follows the federal 503A framework. [1] [2] [3] [4] [5] [6] [8]

Compounded GLP-1 access in Massachusetts

Because compounded GLP-1s are injectable sterile preparations, an out-of-state telehealth program can ship them into Massachusetts only from a pharmacy that holds a Massachusetts nonresident sterile compounding license, which narrows the pool further. [2] [11]

Research use only sellers in Massachusetts

M.G.L. chapter 94 (food and drugs) prohibits selling adulterated or misbranded drugs in Massachusetts, and chapter 112 limits dispensing of prescription drugs to licensed pharmacies and practitioners. [7] [12]

Massachusetts notes on specific peptides

  • Semaglutide: Available branded from any Massachusetts pharmacy by prescription, including by telemedicine from a Massachusetts-licensed physician. Compounded semaglutide injections are limited to the federal patient specific exception since April 22, 2025, and must come from a Massachusetts sterile compounding licensee. [2] [11]
  • BPC-157: Not FDA approved and not on the 503A bulks list. PCAC's July 2026 recommendation is advisory, and until FDA publishes a final rule a 503A pharmacy has no federal basis to compound it from bulk; a state board cannot authorize what federal law does not. Massachusetts pharmacies apply the federal test, and an injectable BPC-157 preparation would also have to come from a pharmacy holding a Massachusetts sterile compounding license (M.G.L. chapter 112, section 39G) or, if shipped from out of state, a nonresident sterile compounding license (section 39J). [2] [3] [9] [10]

How to check a compounding pharmacy in Massachusetts

  1. Search the Massachusetts Board of Registration in Pharmacy (Department of Public Health) license lookup for the pharmacy by name. A pharmacy based elsewhere needs whatever license or registration Massachusetts requires before it ships to you. [1] [2] [3] [4] [5] [6] [8]
  2. Ask whether it operates as a 503A pharmacy or a 503B outsourcing facility, and confirm a 503B claim against FDA's outsourcing facility information (see the verification checklist).
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Massachusetts. [7] [12]

Common questions in Massachusetts

Why are Massachusetts compounding rules stricter than most states?

The 2012 fungal meningitis outbreak traced to the New England Compounding Center in Framingham led to Chapter 159 of the Acts of 2014, which created separate sterile compounding licenses and barred out-of-state compounders from shipping sterile preparations in without a Massachusetts nonresident sterile compounding license. [2] [3] [4]

Can an out-of-state pharmacy ship compounded injectable peptides to me in Massachusetts?

Only if the preparation was made in a pharmacy holding a Massachusetts nonresident sterile compounding license, or in an outsourcing facility with a Massachusetts nonresident registration, under M.G.L. chapter 112, section 39J. Check the Board's license lookup before ordering. [1] [2]

Is compounded semaglutide or tirzepatide still available in Massachusetts?

Only in limited, patient specific cases. The federal shortage allowances ended in 2025, and any compounded injectable must also come from a pharmacy with the right Massachusetts sterile compounding license. [2] [11]

All peptide legal questions for Massachusetts

Sources

  1. [1]Massachusetts Board of Registration in Pharmacy
  2. [2]M.G.L. chapter 112, section 39J, Non-resident pharmacies; licensure; compounded preparations
  3. [3]M.G.L. chapter 112, section 39G, Retail sterile compounding pharmacies; licensure
  4. [4]Chapter 159 of the Acts of 2014, An Act relative to pharmacy practice in the Commonwealth
  5. [5]247 CMR, Board of Registration in Pharmacy regulations (Trial Court Law Libraries compilation)
  6. [6]Board of Registration in Pharmacy: draft regulations, including draft 247 CMR 17.00 (sterile compounding) and 18.00 (non-sterile compounding)
  7. [7]M.G.L. chapter 94, Inspection and sale of food, drugs and various articles
  8. [8]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  9. [9]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
  10. [10]FDA: Pharmacy Compounding Advisory CommitteeFDA
  11. [11]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
  12. [12]21 U.S.C. 331, Prohibited acts